Projects per year
Personal profile
Biography
I am Pharmacologist interested in analgesics and other psychoactive drugs, particularly cannabinoids and opioids. My lab studies how opioids, cannabinoids and related molecules interact with G protein coupled receptors and ion channels to exert their effects. Currently my work is focussed on how clinically used opioids interact with naturally occuring variants of human opioid receptors, the pharmacology and toxicity of emerging synthetic cannabinoid receptors agonists (Spice/K2) and the molecular mechanisms underlying the potential therapeutic actions of cannabis and its components.
Education/Academic qualification
Pharmacology, PhD, University of Washington (UW)
Pharmacology, Genetics, BSc (Hons), University of Sydney
Fingerprint Dive into the research topics where Mark Connor is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 3 Similar Profiles
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Projects
Development of next-generation targeted therapies for epilepsy and pain based on cannabinoid derivatives
Bladen, C. & Connor, M.
3/07/17 → …
Project: Research
Advanced protein quantification capability
Walker, A. K., Lee, A., Connor, M., Atkin, J., Lim, E., Baker, M. S., Rizos, H., Phillips, J. K., Yang, S. & Blair, I.
1/01/17 → …
Project: Research
Mechanisms underlying the repellent effects of predator odours in rodents
Connor, M., McGregor, I., Crowther, M. & Banister, S.
1/01/16 → …
Project: Research
The pharmacology and toxicity of synthetic cannabinoids
Connor, M., Kassiou, M. & McGregor, I.
1/01/16 → …
Project: Research
High-content screening platform
Atkin, J., Connor, M., Blair, I., Rizos, H., Phillips, J. K. & Laird, A.
1/01/19 → 31/12/19
Project: Research
Research Outputs
Differential activation of G protein-mediated signaling by synthetic cannabinoid receptor agonists
Sachdev, S., Banister, S. D., Santiago, M., Bladen, C., Kassiou, M. & Connor, M., 1 Apr 2020, In : Pharmacology Research & Perspectives. 8, 2, p. 1-10 10 p., e00566.Research output: Contribution to journal › Article
Open Access
File
3
Downloads
(Pure)
Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists
Gillis, A., Gondin, A. B., Kliewer, A., Sanchez, J., Lim, H. D., Alamein, C., Manandhar, P., Santiago, M., Fritzwanker, S., Schmidel, F., Katte, T. A., Reekie, T., Grimsey, N. L., Kassiou, M., Kellam, B., Krasel, C., Halls, M. L., Connor, M., Lane, J. R., Schulz, S. & 2 others, , 31 Mar 2020, In : Science Signaling. 13, 625, p. 1-18 18 p., eaaz3140.Research output: Contribution to journal › Article
2
Citations
(Scopus)
Absence of entourage: terpenoids commonly found in Cannabis sativa do not modulate the functional activity of Δ9-THC at human CB1 and CB2 receptors
Santiago, M., Sachdev, S., Arnold, J. C., McGregor, I. & Connor, M., 1 Sep 2019, In : Cannabis and Cannabinoid Research. 4, 3, p. 165-176 12 p.Research output: Contribution to journal › Article
Open Access
File
8
Citations
(Scopus)
10
Downloads
(Pure)
Brodifacoum does not modulate human cannabinoid receptor-mediated hyperpolarization of AtT20 cells or inhibition of adenylyl cyclase in HEK 293 cells
Sachdev, S., Boyd, R., Grimsey, N. L., Santiago, M. & Connor, M., 25 Sep 2019, In : PeerJ. 2019, 9, p. 1-15 15 p., e7733.Research output: Contribution to journal › Article
Open Access
File
5
Downloads
(Pure)
Cannabichromene is a Cannabinoid CB2 receptor agonist
Udoh, M., Santiago, M., Devenish, S., McGregor, I. & Connor, M., Dec 2019, In : British Journal of Pharmacology. 176, 23, p. 4537-4547 11 p.Research output: Contribution to journal › Article
4
Citations
(Scopus)